Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Cannabis Bioscience International Holdings (CBIH) Cash & Equivalents (2022 - 2026)

Cannabis Bioscience International Holdings filings provide 5 years of Cash & Equivalents readings, the most recent being $90.0 for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 83.58% to $90.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $90.0, a 83.58% decrease, with the full-year FY2025 number at $12952.0, up 1615.5% from a year prior.
  • Cash & Equivalents reached $90.0 in Q1 2026 per CBIH's latest filing, down from $132.0 in the prior quarter.
  • The five-year high for Cash & Equivalents was $25655.0 in Q1 2023, with the low at $90.0 in Q1 2026.
  • A 5-year average of $5800.4 and a median of $881.5 in 2024 define the central range for Cash & Equivalents.
  • Year-over-year, Cash & Equivalents crashed 98.6% in 2023 and then skyrocketed 1615.5% in 2025.
  • Year by year, Cash & Equivalents stood at $24089.0 in 2022, then plummeted by 98.6% to $337.0 in 2023, then skyrocketed by 197.33% to $1002.0 in 2024, then plummeted by 86.83% to $132.0 in 2025, then crashed by 31.82% to $90.0 in 2026.
  • Per Business Quant, the three most recent readings for CBIH's Cash & Equivalents are $90.0 (Q1 2026), $132.0 (Q4 2025), and $223.0 (Q3 2025).